These are documentation pages, not recommendations. Each one records identity facts, a structured verification table with dates, lots and methods from Janoshik, Medutest, PeptideMeter and VendorInvestigate, an assessment of documentation quality, community reviews, named maintainers and a review date. Each row and each page links the supplier's own storefront, marked nofollow and sponsored, so a claim here can be read against the seller's own copy — we take nothing from any of them and a link is not a recommendation.
Research compound manufacturer trading as FGP (flourishglobalpeptide.net), based in Chengdu, China, established 2019. Janoshik-tested and verified by Medutest, PeptideMeter and…
4 verification records · 4 services · reviewed by 9 Sep 2026
Research peptide supplier founded 2017 in Qingdao, Shandong, China, operating a worldwide warehouse network with Janoshik third-party testing. Sells direct at qingdaosigma.com.
4 verification records · 3 services · reviewed by 19 Aug 2026
Research compound manufacturer trading as HJ (hubeijianxiang.net), based in Xianning, China, established 2015. Janoshik-tested and verified by Medutest, PeptideMeter and VendorInvestigate;…
4 verification records · 4 services · reviewed by 24 Aug 2026
Research compound manufacturer trading as KP (keruipeptides.com), based in Zhuhai, China, established 2016. Janoshik-tested and verified by Medutest, PeptideMeter and VendorInvestigate;…
4 verification records · 4 services · reviewed by 14 Oct 2026
Major peptide synthesis company founded 1998 in Shanghai, China. ISO 9001 and cGMP certified with more than 1,500 employees and over 200 patents, supplying custom peptides and amino acid…
5 verification records · 4 services · reviewed by 16 Dec 2026
Research compound manufacturer trading as ERP (erpbiotechnology.com), based in Shanghai, China, established 2018. Janoshik-tested and verified by Medutest, PeptideMeter and…
4 verification records · 4 services · reviewed by 28 Sep 2026
Research-grade peptide, SARM, injectable and raw-material supplier based in Wuhan, Hubei, China. Janoshik-tested, with a substantial body of published third-party test reports. Sells…
5 verification records · 4 services · reviewed by 5 Aug 2026
Research compound manufacturer trading as QST (qingdaosabertechnology.com), based in Qingdao, China, established 2017. Janoshik-tested and verified by Medutest, PeptideMeter and…
4 verification records · 4 services · reviewed by 11 Aug 2026
Research compound manufacturer trading as SGN (sangonbio.com), based in Shanghai, China, established 2004. Janoshik-tested and verified by Medutest, PeptideMeter and VendorInvestigate;…
4 verification records · 4 services · reviewed by 2 Dec 2026
Research compound manufacturer trading as MKM (mokemeibiotechnology.com), based in Xi'an, China, established 2016. Janoshik-tested and verified by Medutest, PeptideMeter and…
4 verification records · 4 services · reviewed by 16 Sep 2026
Research compound manufacturer and exporter trading as TFC, based in Tianjin, China. Janoshik-tested and verified by PeptideMeter, Medutest and VendorInvestigate; supplies peptides, SARMs…
4 verification records · 4 services · reviewed by 2 Sep 2026
Research compound manufacturer trading as QYB (qyaobiopeptides.com), based in Shanghai, China, established 2008. Janoshik-tested and verified by Medutest, PeptideMeter and…
4 verification records · 4 services · reviewed by 18 Nov 2026
Research-grade peptide and SARM supplier trading as Homopeptide, based in Changsha, Hunan, China. PeptideMeter, Medutest and VendorInvestigate verified, operating a warehouse network with…
4 verification records · 3 services · reviewed by 1 Aug 2026
Peptide supplier based in Nantong, Jiangsu, China, operating a multi-region warehouse network. Janoshik-tested and PeptideMeter verified. Sells direct at ggpeps.net.
4 verification records · 4 services · reviewed by 28 Oct 2026
Factory-direct research peptide manufacturer trading as JEEP Peptides (jeepbio.com), based in Guangzhou, Guangdong, China. Janoshik-tested with a stated GLP-1 specialty; supplies research…
5 verification records · 4 services · reviewed by 18 Jan 2027
Research compound manufacturer trading as CPC (chinesepeptidecompany.net), based in Hangzhou, China, established 2001. Janoshik-tested and verified by Medutest, PeptideMeter and…
4 verification records · 4 services · reviewed by 30 Nov 2026
Research compound manufacturer trading as BCH (bachemholding.com), based in Suzhou, China, established 2003. Janoshik-tested and verified by Medutest, PeptideMeter and VendorInvestigate;…
4 verification records · 4 services · reviewed by 11 Nov 2026
Research compound manufacturer trading as SSA (shanghaisigmaaudley.com), based in Shanghai, China, established 2018. Janoshik-tested and verified by Medutest, PeptideMeter and…
4 verification records · 4 services · reviewed by 22 Oct 2026
Research compound manufacturer trading as WXT (wuxitides.net), based in Wuxi, China, established 2002. Janoshik-tested and verified by Medutest, PeptideMeter and VendorInvestigate.…
5 verification records · 4 services · reviewed by 9 Dec 2026
Research compound manufacturer trading as SWB (shanghaiwibsonbiotechnology.net), based in Shanghai, China, established 2019. Janoshik-tested and verified by Medutest, PeptideMeter and…
4 verification records · 4 services · reviewed by 5 Oct 2026
Peptide API manufacturer and contract development house trading as HYB (hybiopharmaceutical.com), based in Shenzhen, Guangdong, China, established 2003. Janoshik-tested and verified by…
4 verification records · 4 services · reviewed by 8 Feb 2027
Solid-phase peptide synthesis house trading as GenScript Peptides (genscriptpeptides.com), based in Nanjing, Jiangsu, China, established 2002. Janoshik-tested and verified by Medutest,…
4 verification records · 4 services · reviewed by 14 Mar 2027
Research-compound supplier trading as SIG (sigmaaldrich.org), a Shanghai trading company established 2005 that sells against its own specification rather than synthesising in house.…
4 verification records · 4 services · reviewed by 14 Mar 2027
Solid-phase peptide synthesis house trading as PPG (polypeptidegroup.net), based in Hangzhou, Zhejiang, China, established 2006. Janoshik-tested and verified by Medutest, PeptideMeter and…
4 verification records · 4 services · reviewed by 14 Mar 2027
Solid-phase and solution-phase synthesis house trading as Asymchem (asymchem.org), based in Tianjin, China, established 1998. Publishes four independent laboratory reports against each lot…
4 verification records · 4 services · reviewed by 20 Aug 2027
Fmoc solid-phase peptide synthesis house trading as SinoPep (sinopep.net), based in Changzhou, Jiangsu, China, established 2011. Janoshik-tested and verified by Medutest, PeptideMeter and…
4 verification records · 4 services · reviewed by 11 Mar 2027
Solid-phase synthesis house trading as Thermo Fisher Scientific (thermofisherpeptides.com), based in Shanghai, China, established 2006. Publishes four independent laboratory reports…
4 verification records · 4 services · reviewed by 21 Aug 2027
Peptide active-ingredient manufacturer and contract development house trading as AmbioPharm (ambiopharm.net), based in Beijing, China, established 2003. Janoshik-tested and verified by…
4 verification records · 4 services · reviewed by 6 Apr 2027
The 28 above have pages because there are dated, methodical verification records to put on them. The 188 below get named in topics without ever accumulating enough for a page to say anything defensible — too few reports to characterise anything, or results that span more than one band, or documentation that does not stand on its own. They are listed because a threshold nobody can see is not a threshold: the set above reads as earned only if you can see what did not clear it. No page, no rating, no outbound link, and no invented history — where nothing is known the entry says so.
| Supplier | Band | Mentions | What we hold |
|---|---|---|---|
| Trusted Peptide | B | 2 | At 2 submissions the accurate statement is that it is unmeasured. The results cluster. |
| Risynth Bio | B | 8 | Coverage is 8 reports, below the threshold for a documentation record here. Recorded results are mutually consistent. |
| NUPEPS Peptides | B | 4 | 4 results on record: suggestive, and suggestive is not published as more. Internal consistency is not disputed. |
| Hunan GoodPeptides Biotech Co | B | 2 | At 2 submissions the accurate statement is that it is unmeasured. Recorded results are mutually consistent. |
| Bulk Peptide Wholesale | B | 20 | The record runs to 20 submissions and remains open. Internal consistency is not disputed. |
| Paradigm Peptide | B | 16 | 16 results constitute a working sample rather than a testing history. Consistent across the record as it stands. |
| Orbitrex Peptides | B | 17 | The record runs to 17 submissions and remains open. There is no dated, method-stated result on file to build a record page from. |
| Aavant Research | B | 13 | The record runs to 13 submissions and remains open. Consistent across the record as it stands. |
| PeptiAtlas | B | 4 | Coverage is 4 reports, below the threshold for a documentation record here. Internal consistency is not disputed. |
| The Naughty Needle | B | 2 | The evidence base is 2 submissions. Scoping this accordingly: nothing can be concluded. Recorded results are mutually consistent. |
| Lux Synth Aminos | B | 2 | The evidence base is 2 submissions. Scoping this accordingly: nothing can be concluded. Internal consistency is not disputed. |
| Huaian Hanyou Peptide | B | 7 | Coverage is 7 reports, below the threshold for a documentation record here. Consistent across the record as it stands. |
| Lisa Biopeptide | B | 11 | 11 results on record: suggestive, and suggestive is not published as more. No band has been assigned that we would publish as a finding. |
| Lipeptides | B | 7 | The record runs to 7 submissions, thin against catalogue breadth. No result on record contradicts another. |
| NextGen Health | B | 3 | 3 results. Below the threshold this category applies. Recorded results are mutually consistent. |
| OmegAmino | B | 4 | At 4 reports, sampling variation exceeds anything the figures would demonstrate. Consistent across the record as it stands. |
| Xianhong Tong XHT Peptides | B | 5 | The record runs to 5 submissions, thin against catalogue breadth. Between-lot behaviour is unresolved at this sample size. |
| Diju Peptides Wellness and Co | B | 4 | Coverage is 4 reports, below the threshold for a documentation record here. No result on record contradicts another. |
| Zhang TY | B | 4 | 4 submissions support an impression and not a position. Recorded results are mutually consistent. |
| SubQ Society | B | 3 | At 3 submissions the accurate statement is that it is unmeasured. Coverage is too shallow for a documentation assessment either way. |
| Bfflink | B | 13 | 13 results constitute a working sample rather than a testing history. Internal consistency is not disputed. |
| Laicuinuo LCN | B | 7 | At 7 reports, sampling variation exceeds anything the figures would demonstrate. Consistent across the record as it stands. |
| Cellupep | B | 7 | At 7 reports, sampling variation exceeds anything the figures would demonstrate. No result on record contradicts another. |
| Shanghai Leader Peptide Biotechnology | B | 8 | Coverage is 8 reports, below the threshold for a documentation record here. The evidence will not support a band we would stand behind. |
| Peptronix Bio PTB | B | 13 | 13 submissions on record — enough to characterise, short of enough for a record page. A record page would have to assert more than the reports do. |
| Yongkang Nuoao Trading Co | B | 9 | Coverage is 9 reports, below the threshold for a documentation record here. Consistent across the record as it stands. |
| Eros Peptides | B | 3 | Coverage extends to 3 reports and no documentation record has been opened. There is no dated, method-stated result on file to build a record page from. |
| Champion Peptide | B | 6 | 6 results on record: suggestive, and suggestive is not published as more. Consistent across the record as it stands. |
| Bio Pepz | B | 4 | 4 results on record: suggestive, and suggestive is not published as more. Consistent across the record as it stands. |
| Shandong Nuoweiou Medical Technology Co | B | 5 | 5 results on record: suggestive, and suggestive is not published as more. Results reported to date span more than one band. |
| PurePEPS | B | 4 | The record runs to 4 submissions, thin against catalogue breadth. Recorded results are mutually consistent. |
| Rayshine Peptide Biochemicals | C | 6 | At 6 reports, sampling variation exceeds anything the figures would demonstrate. Results are genuine and low. |
| HealthTide Biotech | C | 6 | Coverage is 6 reports, below the threshold for a documentation record here. Results are genuine and low. |
| Dankang BioHealth | C | 12 | 12 submissions support an impression and not a position. Results are genuine and low. |
| Kits4less | C | 7 | The record runs to 7 submissions, thin against catalogue breadth. What is published is a count rather than a characterisation. |
| Huayi Biotechnology | C | 19 | 19 submissions on record — enough to characterise, short of enough for a record page. Below threshold on the evidence held. |
| Anlv Biotechnology | C | 10 | At 10 reports, sampling variation exceeds anything the figures would demonstrate. Results fall below the range occupied by suppliers with records here. |
| Xingtai Pukelai Technology Co | C | 6 | Coverage is 6 reports, below the threshold for a documentation record here. Results fall below the range occupied by suppliers with records here. |
| EHZ Peptides | C | 39 | Coverage is genuine at 39 reports and has not stabilised. Below threshold on the evidence held. |
| Zztai Peptide | C | 30 | The record runs to 30 submissions and remains open. Nothing methodical is on file beyond the submissions counted here. |
| Chimera Peptides | C | 8 | At 8 reports, sampling variation exceeds anything the figures would demonstrate. The band sits beneath the working range. |
| Hangzhou Mandy Biotechnology | C | 14 | 14 results constitute a working sample rather than a testing history. Results are genuine and low. |
| Yabang Peptide | C | 10 | The record runs to 10 submissions, thin against catalogue breadth. Below threshold on the evidence held. |
| Evolve BioPep | C | 7 | At 7 reports, sampling variation exceeds anything the figures would demonstrate. Below threshold on the evidence held. |
| Quenna PMQ | D | 15 | 15 results constitute a working sample rather than a testing history. Results are genuine and low. |
| Nanjing Xiyuxun Technology XYX | D | 3 | The evidence base is 3 submissions. Scoping this accordingly: nothing can be concluded. |
| Welon Peptide Solutions | D | 5 | At 5 reports, sampling variation exceeds anything the figures would demonstrate. Below threshold on the evidence held. |
| Xingtai Lesda Technology | E | 6 | 6 results on record: suggestive, and suggestive is not published as more. The band sits beneath the working range. |
| Qingdao Hongshengda Trading | E | 4 | At 4 reports, sampling variation exceeds anything the figures would demonstrate. The evidence will not support a band we would stand behind. |
| ZZQ Peptides | E | 22 | 22 results constitute a working sample rather than a testing history. Placed below the working band on evidence rather than reputation. |
| Changan District Sheng Peptide Trading | E | 7 | At 7 reports, sampling variation exceeds anything the figures would demonstrate. Results are genuine and low. |
| UWA Elite Peptides | E | 16 | Coverage is genuine at 16 reports and has not stabilised. Results are genuine and low. |
| Hangzhou Youngpeptide Biotechnology HYB | E | 15 | Coverage is genuine at 15 reports and has not stabilised. The documentation that exists does not stand on its own without the reports behind it. |
| Modern Aminos | E | 4 | Coverage is 4 reports, below the threshold for a documentation record here. The band sits beneath the working range. |
| Shanghai OuDaXin New Material Technology Center | E | 43 | Coverage is ample at 43 reports. Volume is not the constraint. The band sits beneath the working range. |
| Shenzhen Jiechuang Trading | E | 8 | 8 submissions support an impression and not a position. Results reported to date span more than one band. |
| Shaanxi Dideu Medichem | E | 6 | 6 results on record: suggestive, and suggestive is not published as more. Volume is the constraint, and it is the only constraint we can speak to. |
| Qingdao VitaConin International Trading | E | 5 | 5 results on record: suggestive, and suggestive is not published as more. Results fall below the range occupied by suppliers with records here. |
| Guangzhou Lengiuanhuang Cosmetics | E | 4 | 4 results on record: suggestive, and suggestive is not published as more. Placed below the working band on evidence rather than reputation. |
| Shanghai JinBei Chemical Technology | B | 18 | 18 submissions on record — enough to characterise, short of enough for a record page. No result on record contradicts another. |
| Peptide Technologies | B | 11 | The record runs to 11 submissions, thin against catalogue breadth. There is no dated, method-stated result on file to build a record page from. |
| Pura Peptides | X | 1 | At 1 submission the accurate statement is that it is unmeasured. Neither a method nor a lot identifier accompanies most of what is published. |
| Peptide Partners | B to C | 64 | 64 results on record, sufficient to characterise the supplier. Results range across bands, which characterises the process. |
| Bfflist AMO | B to C | 63 | 63 submissions is a substantial record; dispersion rather than the mean is the question. Results span more than one band. |
| Pure Tested Peptides | B to C | 7 | 7 submissions support an impression and not a position. Results range across bands, which characterises the process. |
| PeptiSlim | C to E | 38 | Coverage is genuine at 38 reports and has not stabilised. Results range across bands, which characterises the process. |
| Glamgurcraft Innovations Foreign Trade | X | 1 | 1 result. Below the threshold this category applies. |
| HkRoids | B to C | 14 | At 14 reports the trend is legible and the interval is wide. Between-lot variance dominates the central estimate. |
| Yiwu Aozuo Trading Co | B to E | 91 | At 91 reports the sample is adequate and the band decides the rest. Dispersion exceeds what method variation accounts for. |
| Peptide Haven | B | 4 | Coverage is 4 reports, below the threshold for a documentation record here. Consistent across the record as it stands. |
| Atomik Labz | B to C | 40 | 40 submissions on record — enough to characterise, short of enough for a record page. Dispersion exceeds what method variation accounts for. |
| Bulk Peptide Supply | B to E | 20 | Coverage is genuine at 20 reports and has not stabilised. Results range across bands, which characterises the process. |
| M-Peptides | B to C | 17 | Coverage is genuine at 17 reports and has not stabilised. Results span more than one band. |
| Mai Peptide | C to E | 55 | 55 submissions is a substantial record; dispersion rather than the mean is the question. Results span more than one band. |
| Peptidology | B | 16 | 16 submissions on record — enough to characterise, short of enough for a record page. Internal consistency is not disputed. |
| Hazel | X | 1 | Coverage extends to 1 report and no documentation record has been opened. The documentation that exists does not stand on its own without the reports behind it. |
| TCI | X | 1 | The evidence base is 1 submission. Scoping this accordingly: nothing can be concluded. |
| Uther | B to E | 69 | Coverage is ample at 69 reports. Volume is not the constraint. Results span more than one band. |
| Shandong Shengyuan Peptide Technology | B to E | 24 | Coverage is genuine at 24 reports and has not stabilised. Neither a method nor a lot identifier accompanies most of what is published. |
| LiliPeptide | C to E | 185 | Coverage is ample at 185 reports. Volume is not the constraint. |
| Xingruida XDR | B to D | 64 | At 64 reports the sample is adequate and the band decides the rest. The dispersion is the finding. |
| Eternal Peptides | B | 23 | 23 submissions on record — enough to characterise, short of enough for a record page. Volume is the constraint, and it is the only constraint we can speak to. |
| Tianjin Ruiwang New Material Technology Co | B to E | 107 | 107 results on record, sufficient to characterise the supplier. Between-lot behaviour is unresolved at this sample size. |
| Polaris Peptides | B to D | 97 | 97 results on record, sufficient to characterise the supplier. Coverage is too shallow for a documentation assessment either way. |
| Injectify | B to E | 29 | At 29 reports the trend is legible and the interval is wide. Results span more than one band. |
| Precision Peptide Co | B to C | 21 | 21 submissions on record — enough to characterise, short of enough for a record page. Coverage is too shallow for a documentation assessment either way. |
| AKS Chem | X | 1 | 1 result on record, which characterises a vial rather than a supplier. Nothing is known here about the paperwork, which is a statement about our coverage. |
| Reta-Peptide | B to E | 144 | Coverage is ample at 144 reports. Volume is not the constraint. The dispersion is the finding. |
| Peptide-S | B to E | 125 | At 125 reports the sample is adequate and the band decides the rest. Dispersion exceeds what method variation accounts for. |
| Planet Peptide | B to D | 59 | The record runs to 59 submissions across multiple lines. Between-lot variance dominates the central estimate. |
| Henan Sahe Peptide | B to D | 18 | Coverage is genuine at 18 reports and has not stabilised. Results span more than one band. |
| Hunan Ruiwang Technology Center | B to C | 14 | Coverage is genuine at 14 reports and has not stabilised. Results range across bands, which characterises the process. |
| Skye Peptides | B to E | 73 | Coverage is ample at 73 reports. Volume is not the constraint. Dispersion exceeds what method variation accounts for. |
| Nuscience Peptides | B to D | 47 | 47 results on record, sufficient to characterise the supplier. Between-lot variance dominates the central estimate. |
| NextechLabs | B to D | 30 | At 30 reports the trend is legible and the interval is wide. Results span more than one band. |
| Golden Eagle | B to C | 17 | The record runs to 17 submissions and remains open. The dispersion is the finding. |
| Peptide Worldwide | X | 1 | At 1 submission the accurate statement is that it is unmeasured. Unrated: the evidence will not support a band. |
| HK Peptides | B to E | 343 | At 343 reports the sample is adequate and the band decides the rest. Results span more than one band. |
| Nexaph | B to E | 200 | 200 submissions is a substantial record; dispersion rather than the mean is the question. Results span more than one band. |
| BeiBangAn | C to D | 38 | 38 submissions on record — enough to characterise, short of enough for a record page. What is published is a count rather than a characterisation. |
| Shandong Aishi Biotechnology | D to E | 37 | 37 submissions on record — enough to characterise, short of enough for a record page. There is no dated, method-stated result on file to build a record page from. |
| Xingtai Jiachuang Technology | C to E | 31 | Coverage is genuine at 31 reports and has not stabilised. Dispersion exceeds what method variation accounts for. |
| Zenith Jove Peptide ZJ | B to E | 26 | 26 results constitute a working sample rather than a testing history. Results span more than one band. |
| Kerisite Shenzhen International | B to D | 16 | The record runs to 16 submissions and remains open. Results span more than one band. |
| YB Peptide | B to E | 10 | At 10 reports, sampling variation exceeds anything the figures would demonstrate. Results range across bands, which characterises the process. |
| Qing Li Peptide | B to E | 260 | Coverage is ample at 260 reports. Volume is not the constraint. Results range across bands, which characterises the process. |
| Shanxi Qianyecao Biotech QYC | D to E | 66 | 66 submissions is a substantial record; dispersion rather than the mean is the question. Results span more than one band. |
| Verified Peptides | B to C | 34 | 34 submissions on record — enough to characterise, short of enough for a record page. Nothing is known here about the paperwork, which is a statement about our coverage. |
| Hebei Rimao Technology | C to D | 32 | Coverage is genuine at 32 reports and has not stabilised. Between-lot variance dominates the central estimate. |
| Pure Rawz | B to D | 29 | The record runs to 29 submissions and remains open. Between-lot variance dominates the central estimate. |
| Heman Peptide HM | B to E | 29 | The record runs to 29 submissions and remains open. The dispersion is the finding. |
| Shanghai Baoju | B to E | 21 | Coverage is genuine at 21 reports and has not stabilised. Nothing methodical is on file beyond the submissions counted here. |
| ZLZ Peptide | B to E | 199 | Coverage is ample at 199 reports. Volume is not the constraint. |
| Peptide Sciences | B to E | 123 | Coverage is ample at 123 reports. Volume is not the constraint. Results range across bands, which characterises the process. |
| Allen Biotechnology Co ABC | B to E | 43 | Coverage is ample at 43 reports. Volume is not the constraint. |
| Peptide Crafters | B to D | 39 | The record runs to 39 submissions and remains open. Results span more than one band. |
| Simple Peptide | B to D | 26 | 26 results constitute a working sample rather than a testing history. The dispersion is the finding. |
| Top Peptide | C to D | 21 | At 21 reports the trend is legible and the interval is wide. What is published is a count rather than a characterisation. |
| Zen Peptides | B to C | 13 | Coverage is genuine at 13 reports and has not stabilised. Between-lot variance dominates the central estimate. |
| Amino Lair | B to D | 12 | 12 results on record: suggestive, and suggestive is not published as more. Results span more than one band. |
| Oupeptide | B to E | 149 | 149 submissions is a substantial record; dispersion rather than the mean is the question. Results range across bands, which characterises the process. |
| Paramount Peptides | B to E | 65 | 65 results on record, sufficient to characterise the supplier. There is no dated, method-stated result on file to build a record page from. |
| Yimei | B to E | 54 | 54 results on record, sufficient to characterise the supplier. Between-lot variance dominates the central estimate. |
| LSPL | C to E | 40 | The record runs to 40 submissions and remains open. Results range across bands, which characterises the process. |
| Royal Peptides | B to C | 30 | 30 results constitute a working sample rather than a testing history. Results span more than one band. |
| Shenzhen Loga Tech LG LOGA | B to E | 21 | The record runs to 21 submissions and remains open. Between-lot behaviour is unresolved at this sample size. |
| ZhuoYan lab | C to E | 30 | The record runs to 30 submissions and remains open. Results span more than one band. |
| Astro Peptides | B to E | 29 | At 29 reports the trend is legible and the interval is wide. Dispersion exceeds what method variation accounts for. |
| Mix Peptides | D to E | 29 | The record runs to 29 submissions and remains open. Results range across bands, which characterises the process. |
| Science | B to C | 12 | 12 results on record: suggestive, and suggestive is not published as more. The dispersion is the finding. |
| TSC Top Supplements China | C to E | 99 | 99 submissions is a substantial record; dispersion rather than the mean is the question. Dispersion exceeds what method variation accounts for. |
| HXNet | C to E | 91 | Coverage is ample at 91 reports. Volume is not the constraint. Results range across bands, which characterises the process. |
| Xian Yihang Technology | C to E | 48 | Coverage is ample at 48 reports. Volume is not the constraint. Results range across bands, which characterises the process. |
| Haikou Mingheng Technology | B to C | 16 | The record runs to 16 submissions and remains open. Dispersion exceeds what method variation accounts for. |
| SRY Labs | B to E | 111 | At 111 reports the sample is adequate and the band decides the rest. Dispersion exceeds what method variation accounts for. |
| Accelerate Labs | B to E | 20 | The record runs to 20 submissions and remains open. Results range across bands, which characterises the process. |
| PurePeptides | B to E | 15 | Coverage is genuine at 15 reports and has not stabilised. Dispersion exceeds what method variation accounts for. |
| Regenerative Research | X | 2 | The evidence base is 2 submissions. Scoping this accordingly: nothing can be concluded. Deliberately unassigned. |
| Zhejiang Yichenkang Biotechnology | B to E | 58 | Coverage is ample at 58 reports. Volume is not the constraint. Results range across bands, which characterises the process. |
| Biolongevity Labs | B to E | 33 | 33 results constitute a working sample rather than a testing history. Results range across bands, which characterises the process. |
| Alpha-Gen | B to E | 30 | 30 results constitute a working sample rather than a testing history. Results range across bands, which characterises the process. |
| LN Peptides | B to E | 28 | At 28 reports the trend is legible and the interval is wide. Coverage is too shallow for a documentation assessment either way. |
| Forever Young Pharmacy | B to E | 26 | At 26 reports the trend is legible and the interval is wide. Results range across bands, which characterises the process. |
| Prime Peptides | B to E | 19 | 19 submissions on record — enough to characterise, short of enough for a record page. Between-lot variance dominates the central estimate. |
| Haikou Mingheng Biotechnology | D to E | 11 | The record runs to 11 submissions, thin against catalogue breadth. Results span more than one band. |
| Dragon Pharma | X | 1 | At 1 submission the accurate statement is that it is unmeasured. Deliberately unassigned. |
| Liberty Peptides | B to E | 16 | 16 submissions on record — enough to characterise, short of enough for a record page. Results range across bands, which characterises the process. |
| Amino Asylum | B to C | 15 | At 15 reports the trend is legible and the interval is wide. Results range across bands, which characterises the process. |
| Amino Amigos | B to E | 37 | At 37 reports the trend is legible and the interval is wide. The evidence will not support a band we would stand behind. |
| Platinum Cryo | B to E | 24 | 24 submissions on record — enough to characterise, short of enough for a record page. A record page would have to assert more than the reports do. |
| Elite Research USA | B to E | 47 | At 47 reports the sample is adequate and the band decides the rest. Dispersion exceeds what method variation accounts for. |
| Limitless Life Nootropics | B to D | 22 | At 22 reports the trend is legible and the interval is wide. A record page would have to assert more than the reports do. |
| Oasis Peptides | B to E | 16 | At 16 reports the trend is legible and the interval is wide. Results range across bands, which characterises the process. |
| Suaway Lab Research | B to E | 39 | 39 submissions on record — enough to characterise, short of enough for a record page. The interval around any figure here is wider than the figure. |
| Pharma Grade Peptides | B to E | 18 | 18 submissions on record — enough to characterise, short of enough for a record page. What is published is a count rather than a characterisation. |
| PeptiLab Research | B to E | 15 | At 15 reports the trend is legible and the interval is wide. The dispersion is the finding. |
| Tydes | C to E | 41 | 41 submissions is a substantial record; dispersion rather than the mean is the question. Dispersion exceeds what method variation accounts for. |
| Loti Labs | B to E | 32 | 32 submissions on record — enough to characterise, short of enough for a record page. Results span more than one band. |
| Wolverine Peptides | X | 1 | 1 result. Below the threshold this category applies. Unrated: the evidence will not support a band. |
| Amplified Amino | C to E | 12 | Coverage is 12 reports, below the threshold for a documentation record here. The dispersion is the finding. |
| Alimo Peptide | D to E | 7 | Coverage is 7 reports, below the threshold for a documentation record here. Dispersion exceeds what method variation accounts for. |
| Richards Biotech Simply Richards | X | 1 | 1 result on record, which characterises a vial rather than a supplier. No band assigned, and none is imputed. |
| Coastal Peptides | B to E | 26 | The record runs to 26 submissions and remains open. Results range across bands, which characterises the process. |
| Peptides 4 Research | C to E | 20 | At 20 reports the trend is legible and the interval is wide. Dispersion exceeds what method variation accounts for. |
| Deuschem | B to E | 29 | At 29 reports the trend is legible and the interval is wide. Between-lot variance dominates the central estimate. |
| Hybiopeptides | X | 1 | Coverage extends to 1 report and no documentation record has been opened. Unrated: the evidence will not support a band. |
| Peptide Gurus | B to E | 45 | The record runs to 45 submissions across multiple lines. There is no dated, method-stated result on file to build a record page from. |
| Swiss Chems | C to E | 9 | At 9 reports, sampling variation exceeds anything the figures would demonstrate. Between-lot variance dominates the central estimate. |
| WllyBIO | X | 1 | At 1 submission the accurate statement is that it is unmeasured. No band assigned, and none is imputed. |
| Biolabshop Limited | C to E | 6 | At 6 reports, sampling variation exceeds anything the figures would demonstrate. Between-lot variance dominates the central estimate. |
| Peptides For Sale | D to E | 21 | 21 submissions on record — enough to characterise, short of enough for a record page. Dispersion exceeds what method variation accounts for. |
| NuLife Peptides | B | 6 | The record runs to 6 submissions, thin against catalogue breadth. Recorded results are mutually consistent. |
| Wuhan Newtop Biotech | X | 2 | 2 results on record, which characterises a vial rather than a supplier. Deliberately unassigned. |
| LOOKBiotech | X | 2 | 2 results. Below the threshold this category applies. Deliberately unassigned. |
| PRIVATE | X | 2 | The evidence base is 2 submissions. Scoping this accordingly: nothing can be concluded. No band assigned, and none is imputed. |
| Peptide Ark | X | 2 | 2 results on record, which characterises a vial rather than a supplier. No band. Recorded as an absence. |
| Zhuoyue Biotechnology | X | 1 | 1 result on record, which characterises a vial rather than a supplier. No score, there being nothing to score. |
| Hebei Chengtong Technology | X | 1 | The evidence base is 1 submission. Scoping this accordingly: nothing can be concluded. Deliberately unassigned. |
| Coffee and Peppers | X | 1 | At 1 submission the accurate statement is that it is unmeasured. No band. Recorded as an absence. |
| Marvel Peptide | X | 1 | 1 result on record, which characterises a vial rather than a supplier. Deliberately unassigned. |
| HK Fat Cat | X | 1 | 1 result. Below the threshold this category applies. No band assigned, and none is imputed. |
| Guangzhou Yuao Trading | X | 1 | The evidence base is 1 submission. Scoping this accordingly: nothing can be concluded. No band. Recorded as an absence. |
| PepKits | X | 1 | 1 result. Below the threshold this category applies. Deliberately unassigned. |
| Lejian Biotech Peptide | X | 1 | Coverage extends to 1 report and no documentation record has been opened. No score, there being nothing to score. |
| PepLab Solutions | X | 1 | 1 result on record, which characterises a vial rather than a supplier. Unrated: the evidence will not support a band. |
| Explicit Sarms | X | 1 | 1 result. Below the threshold this category applies. No band. Recorded as an absence. |
| Weifang Xingbei International Trade | X | 1 | The evidence base is 1 submission. Scoping this accordingly: nothing can be concluded. No band assigned, and none is imputed. |
| Advanced Technology and Industrial | X | 1 | 1 result. Below the threshold this category applies. No score, there being nothing to score. |
A supplier here has not been assessed. The band and the report count are what the wider market has published, not our finding; the note says what is thin about it and nothing more. Absence from the documented set above is a statement about how little we hold, not an allegation about the company — and we do not publish an address, a founding date or a testing history for a supplier where we hold none.